CJC-1295 DAC 5mg

Researchers evaluating where to buy CJC-1295 DAC for research should begin with compound identity, batch-specific documentation, and RUO labeling rather than consumer-facing claims. CJC-1295 is listed in PubChem as a chemical compound record under CID 91971820, with a molecular formula of C165H269N47O46, giving research teams a database point of comparison for identity documentation [1]. This Pure Lab Peptides guide explains how to review CJC-1295 DAC peptide documentation, published literature, analytical testing, and procurement records in a research-use-only context.

• CJC-1295 DAC is discussed in published literature as a synthetic GHRH analog and albumin-associated GRF analog [2].
• CJC-1295 DAC research should be reviewed through compound identity, pathway context, and documentation quality, not product-use claims.
• COA documentation should support lot-level review, including compound name, batch identifier, testing method, purity statement, and date.
• HPLC can support peptide purity review, while LC-MS or related mass spectrometry methods can support identity verification when paired with suitable reference data [11] [12].
• Published literature describes model-specific findings; it does not establish the properties or suitability of a supplier’s research material.
• CJC-1295 DAC materials from Pure Lab Peptides are intended for laboratory research use only.

Fast Answer: What Should Researchers Check Before They Buy CJC-1295 DAC for Research?

Researchers looking to buy CJC-1295 DAC for research should first review RUO labeling, the batch-specific COA, peptide identity data, purity testing, lot traceability, and supplier documentation. Products discussed in this article are intended for laboratory research use only and are not intended for human or animal consumption. Published CJC-1295 literature provides research context, not verification of a supplier’s product.

What Documentation Should Come First for Research Procurement?

The first review layer is the product documentation set: compound name, RUO label, lot number, COA, testing method, and storage record. For CJC-1295 DAC research, the documentation should make it easy to connect the product listing to the certificate of analysis and the batch-specific analytical record.

A documentation-first review also reduces ambiguity around similar names. CJC-1295 DAC, CJC-1295 with DAC, and DAC peptide language can appear in research discussions, so the procurement record should identify the exact material being evaluated.

ICH Q2(R2) explains that analytical procedure validation concerns whether an analytical procedure is fit for its intended purpose, including common measurements such as identity, purity, and quantitative or qualitative measurements [13].

For research procurement, that means the COA should not be treated as decoration. It should be checked against the lot number, product name, testing method, date, and supplier record.

What Is CJC-1295 DAC in Research Literature?

CJC-1295 DAC is discussed in scientific literature as a long-acting GHRH analog connected to growth hormone-releasing factor research [2]. The DAC element is commonly described in the literature as drug affinity complex chemistry, with albumin association used to change the research compound’s persistence profile in study settings [2] [3].

This article does not position the compound for personal or clinical application. It treats CJC-1295 DAC as a research peptide requiring careful documentation review.

Compound Identity and Research Classification

PubChem provides a chemical record for CJC-1295 that can support identity cross-checking alongside supplier documentation and batch-specific analytical data [1].

CJC-1295 DAC is classified in GHRH analog research. The literature on GHRH and the GHRH receptor provides its pathway context [6].

How Does the DAC Peptide Concept Fit Laboratory Research?

The DAC peptide concept is relevant because published CJC-1295 research describes albumin bioconjugate design and long-lasting GRF analog characterization [2].

Researchers should not treat DAC language as a product claim. It is a signal to verify compound identity, labeling, and analytical documentation.

Batch-Specific Documentation for CJC-1295 DAC Peptide

Batch-specific documentation helps confirm that the material being reviewed matches the lot described in the COA. A batch record should connect the CJC-1295 DAC peptide name, lot number, purity statement, identity method, and testing date.

Evaluating a CJC-1295 DAC Research Material Listing

What Makes a Research Material Listing Clear?

A clear research material listing identifies the compound, research-only status, available documentation, and batch-specific testing record. It should also keep supplier language aligned with the COA and label.

A useful listing avoids vague claims. It directs attention to analytical testing, identity review, purity documentation, and lot traceability.

RUO Labeling and Product-Page Clarity

RUO labeling should be clear, visible, and consistent across the product page, label, and supporting documents.

Consistent RUO labeling helps procurement teams distinguish research-only materials from products intended for clinical use.

Scientific Background: CJC-1295 DAC and GHRH Analog Research

GHRH research centers on growth hormone-releasing hormone, its receptor, and pituitary pathway biology. Reviews on GHRH and its receptor describe the molecular framework for understanding pituitary somatotroph signaling and GHRH receptor biology [6] [7].

Published studies evaluate CJC-1295 DAC as a long-acting GHRH analog. Those findings provide academic context, not verification of a supplier’s material.

Growth Hormone-Releasing Factor Context in Published Literature

Growth hormone-releasing factor, also called GHRH in much of the literature, provides the biological reference point for CJC-1295 DAC. Jetté and colleagues described hGRF(1-29)-albumin bioconjugates and identified CJC-1295 as a long-lasting GRF analog in a peer-reviewed study [2].

For product-page readers, the key takeaway is not product action. It is that CJC-1295 DAC documentation should be reviewed in the context of GHRH analog identity and pathway literature.

What Role Does the Pituitary Pathway Context Play?

NCBI Gene describes GHRHR as encoding a receptor for growth hormone-releasing hormone, with receptor binding connected to pituitary signaling biology [4]. UniProt similarly describes the reviewed human GHRHR entry as a GRF receptor coupled to G proteins and adenylyl cyclase signaling [5].

That pathway context helps define the research lane. It does not establish an RUO product application.

How Does CJC-1295 DAC Research Fit Endocrine Pathway Models?

CJC-1295 DAC research fits endocrine pathway models through GHRH analog and receptor-pathway literature. The compound’s scientific background is tied to GHRH receptor signaling, albumin-associated peptide design, and model-specific GH/IGF-1 axis observations in published studies [2] [9].

Receptor Signaling Context Without Product Claims

GHRHR is generally described as a G protein-coupled receptor associated with adenylyl cyclase signaling in authoritative protein and gene databases [4] [5].

Why Pathway Relevance Is Not a Product Claim?

A pathway connection tells researchers where the compound appears in the literature. It does not prove that a product listing has any effect beyond its documented identity and testing record.

Scientific background explains the research context; COA documentation and analytical testing support review of the specific material being procured.

Published Models and Their Research Limits

CJC-1295 has appeared in model-specific literature, including GHRH knockout mouse research and studies outside RUO product use [8] [3]. Those studies are part of the evidence landscape, not instructions or claims for RUO materials.

The safer reading is model-first. Identify the model, the measured endpoint, the limitation, and the boundary before interpreting the study.

Published Literature Context for CJC-1295 DAC Research

Published CJC-1295 DAC research includes compound characterization, pharmacokinetic literature, preclinical model work, and proteomic observations [2] [3] [8] [9].

Supplier documentation still needs its own review.

Evaluating Research Sources

A strong source filter gives priority to peer-reviewed literature, official databases, and analytical chemistry references.

For this article, compound identity, receptor context, and analytical testing are supported by PubChem, NCBI, UniProt, PubMed-indexed research, ICH, and FDA resources [1] [4] [13].

What Literature Signals Matter for Research Documentation?

The most useful literature signals are compound identity, analog class, receptor pathway context, model type, analytical method, and stated limitations. For CJC-1295 DAC, literature on albumin bioconjugates and long-acting GHRH analogs is directly relevant to identity context [2].

Procurement teams should pair those signals with supplier-specific documents. Literature can inform the review, but it cannot replace batch-specific testing.

Evidence Interpretation Framework for GHRH Analog Literature

Evidence interpretation separates source type, model type, and relevance to the material under review.

Mechanistic Findings Versus Product-Page Claims

Mechanistic findings describe what researchers observed in a defined model. Product-page claims describe what a product is being positioned to do.

Those two categories must stay separate.

How Research Literature Stays Separate From Product Claims?

Research literature can describe compound class, pathway context, model findings, and analytical methods.

Some published literature outside the scope of RUO product use has examined this compound class in human study settings. That literature should not be interpreted as a use claim for research-use-only materials [3].

Why Study Findings Should Not Become Product Claims?

Study findings depend on study design, model type, methods, and limitations. Product claims are supplier statements about a research material.

What Does Research-Only Status Mean?

CJC-1295 DAC research material is not intended for wellness, fitness, cosmetic, or clinical use. Model-specific literature does not establish the performance of a supplier’s product.

Why COA Documentation Matters for CJC-1295 DAC?

COA documentation matters because it is the record that links a specific lot to its reported testing data. For research buyers, a CJC-1295 DAC COA should clarify identity, purity, method, date, lot number, and testing source.

The COA should be reviewed alongside the label and product listing. Consistency across those materials is a core part of procurement quality.

What a Certificate of Analysis Should Clarify?

A certificate of analysis should clarify what was tested, which lot was tested, what method was used, and what the reported result means. FDA analytical guidance discusses documentation of identity, quality, purity, and related analytical procedure information in regulated analytical contexts [14].

For RUO procurement, those principles translate into a practical documentation check. The COA should be specific enough to support laboratory recordkeeping.

Batch-Specific COA Consistency Review

A batch-specific COA should match the product name and lot number shown on the product listing or label. A generic COA is less useful because it may not show whether the document applies to the exact lot being reviewed.

For CJC-1295 DAC peptide procurement, batch specificity is one of the easiest quality signals to check. It is also one of the most important.

Why COA Dates and Lot Numbers Matter?

COA dates and lot numbers connect a document to a point in time and to a defined batch. Without those details, the document is harder to verify against supplier records.

This does not require complex interpretation. It requires careful matching.

Analytical Testing Review for CJC-1295 DAC Peptide

Analytical testing review should ask what each method can and cannot support. HPLC is widely used in peptide analysis and purification, while LC-MS connects liquid chromatography with mass spectrometry for peptide identification and measurement workflows [11] [12].

For CJC-1295 DAC peptide documentation, HPLC and LC-MS should be read together when both are available. Purity and identity are related, but they are not the same documentation question.

How HPLC Supports Peptide Purity Review?

HPLC separates compounds based on chromatographic behavior, making it useful for peptide analysis and purity-related review [11]. A COA may include an HPLC purity statement, chromatogram, or related method note.

Researchers should confirm whether the COA states the method clearly. The method name alone is useful, but supporting detail improves documentation value.

How LC-MS Supports Peptide Identity Verification?

LC-MS supports identity review by combining chromatographic separation with mass spectrometry data. LC-MS-based peptide identification commonly relies on observed spectral measurements compared with theoretical or previously observed measurements [12].

For CJC-1295 DAC, LC-MS documentation can help support identity verification when it is batch-specific and aligned with the expected compound record. It should not be treated as a substitute for the entire documentation package.

Mass Spectrometry Signals in Documentation Review

Mass spectrometry signals can support identity evaluation through mass-related evidence and fragmentation patterns when appropriate. A CJC-1295 identification study in analytical literature used mass spectrometric interpretation to characterize a peptide sequence consistent with CJC-1295 [10].

For product-page review, the practical point is documentation quality. Mass data should connect to the lot being evaluated.

Lot Traceability and Supplier Documentation Standards

Lot traceability helps research buyers follow a material from listing to label to COA. It supports a basic question: do the supplier records describe the same research material?

Strong documentation standards do not rely on one isolated statement. They create consistency across every visible record.

What Research Buyers Should Compare Across Supplier Records?

Research buyers should compare the product name, lot number, COA date, testing method, purity statement, identity statement, and storage notes. If any of those elements conflict, the procurement team should request clarification before making a research purchasing decision.

This comparison is especially useful for compounds with naming variations.

RUO Labeling Consistency Across Supplier Materials

RUO labeling should be consistent across the product page, label, COA, and supporting documents. FDA guidance on RUO/IUO labeling underscores that research-only labeling should be consistent with intended research positioning [17].

If supplier materials mix RUO labeling with consumer-use claims, request clarification before procurement.

Storage Documentation and Product Listing Consistency

Storage documentation should be treated as part of the product record. ICH Q1A(R2) describes stability testing as a way to evaluate how quality varies with environmental factors such as temperature, humidity, and light [15].

For research peptides, storage notes should be recorded as supplier documentation, not improvised from general expectations. If the listing and COA mention storage information, those records should match.

How Storage Notes Support Research Material Review?

Storage notes support research material review by creating a record of the supplier’s stated handling conditions. Peptide stability can be affected by intrinsic and external factors, including environmental conditions, as reviewed in peptide stability literature [16].

What Listing Details Should Match Supplier Documentation?

The listing details should match the supplier documentation for compound name, lot number, material format, testing claims, and storage notes. If the page references purity or identity data, the COA should support that reference.

For CJC-1295 DAC research procurement, mismatch is the signal to pause. Documentation should clarify, not create extra interpretation work.

Common Misunderstandings About CJC-1295 DAC for Research

Literature Context Versus Product Positioning

Published literature can describe GHRH analog studies, receptor context, and analytical findings.

A literature citation does not make a supplier product equivalent to a study material. It only supports the scientific context being discussed.

Buy CJC-1295 DAC for Research: Procurement Review Checklist

Researchers comparing options to buy CJC-1295 DAC for research should use a structured procurement checklist. The checklist should confirm that the product listing, COA, label, and supplier documentation all point to the same research material.

A practical workflow can stay documentation-focused:

1. Verify the compound name, lot number, and label match across documents.
2. Review the batch-specific COA.
3. Check whether the purity testing method is listed.
4. Confirm whether identity testing is supported by LC-MS or another suitable analytical method.
5. Review chromatogram or mass data when available.
6. Check the COA date and lab source.
7. Document storage and handling requirements in a laboratory record.

What Labs Compare Before They Buy CJC-1295 DAC for Research?

Labs should compare documentation, not marketing language. The most useful review points are identity record, purity method, COA specificity, lot traceability, RUO labeling, storage notes, and supplier clarity.

A quality-focused procurement review also checks what the page avoids. It should avoid personal-use framing and unsupported claims.

Documentation Review for Research Procurement

Use this checklist before selecting any RUO CJC-1295 DAC peptide material:

• Verify that the compound is labeled for research use only.
• Review the batch-specific certificate of analysis.
• Confirm that purity data are supported by analytical testing.
• Check that the lot number on the COA matches the product documentation.
• Compare compound name, molecular formula, and identity data across documentation.
• Assess whether the product page avoids consumer-facing or clinical-use claims.
• Document storage and handling conditions in a laboratory record.

Pure Lab Peptides supplies compounds for laboratory research use only. Products are not intended for human or animal consumption, diagnostic use, therapeutic use, clinical use, veterinary use, or as food, drugs, cosmetics, dietary supplements, or household products. Researchers are responsible for ensuring lawful, appropriate handling and use in accordance with applicable regulations and institutional guidelines.

Review the product-page documentation, COA details, and RUO labeling before evaluating this compound for laboratory research.

FAQs

What does research use only mean for CJC-1295 DAC?

Research use only means CJC-1295 DAC is intended solely for laboratory research contexts. Review compound identity, product documentation, the COA, analytical testing, and lot traceability. The material is not intended for human, animal, personal, wellness, or clinical use.

What should researchers consider before they buy CJC-1295 DAC for research?

Researchers should consider documentation quality before they buy CJC-1295 DAC for research. Key review points include the batch-specific COA, lot number, product label, supplier documentation, and whether analytical testing supports peptide identity and purity.

How does albumin binding relate to peptide half-life in CJC-1295 DAC literature?

Albumin binding relates to peptide half-life as a literature concept connected to the DAC design discussed in CJC-1295 research. Published studies describe CJC-1295 as a long-lasting GRF analog, but that information should remain scientific context rather than product positioning [2]. Researchers should connect this concept to identity documentation, not applied claims.

What molecular identity details can support CJC-1295 DAC documentation review?

Molecular identity details can support CJC-1295 DAC documentation review by giving researchers comparison points for the product record. These may include molecular weight, molecular formula, peptide sequence when verified, and naming consistency across the COA and supplier documentation. PubChem provides a compound record for CJC-1295 that can support identity cross-checking [1].

How should published literature about CJC-1295 DAC be interpreted?

Published literature about CJC-1295 DAC should be interpreted as research context, not product-page proof. Literature may discuss GHRH analog research, receptor pathway models, plasma measurements, or in vitro laboratory research, but each finding depends on its model and methods. The safer review approach separates study context from RUO product documentation.

What role does cell signaling context play in CJC-1295 DAC research?

Cell signaling context places CJC-1295 DAC within GHRH receptor pathway research. Authoritative databases describe GHRHR in relation to G protein signaling and cyclic adenosine monophosphate pathway context [4] [5]. That information supports research classification, not claims about a supplier’s product.

---

Researchers Cited in This Guide

The researchers listed below are cited for relevant published work. Their inclusion does not imply that they wrote, reviewed, or endorsed this guide or Pure Lab Peptides products.

Lawrence A. Frohman

Author profile: ASCI Directory

Lawrence A. Frohman is recognized for published work on GHRH analog research, pituitary pathway biology, and CJC-1295 literature cited in this article. The selected publications concern endocrine pathway models, serum protein profiles, and model-specific findings. These studies provide scientific context and do not replace supplier documentation or batch-specific testing.

Selected publications:

• A peer-reviewed study relevant to CJC-1295 GHRH analog literature — Journal of Clinical Endocrinology & Metabolism, 2006. DOI: 10.1210/jc.2005-1536. PMID: [16352683].
• A publication examining CJC-1295 and serum protein profile research — Growth Hormone & IGF Research, 2009. DOI: 10.1016/j.ghir.2009.03.001. PMID: [19386527].

Roberto Salvatori

Author profile: Johns Hopkins University Profile

Roberto Salvatori is recognized for published work on GHRH pathway models and the preclinical background referenced here. The selected publications examine GHRH knockout and gene-targeted models relevant to pathway research. Their findings depend on model design and do not establish the properties of a supplier’s research material.

Selected publications:

• A preclinical GHRH knockout model publication relevant to CJC-1295 research — American Journal of Physiology-Endocrinology and Metabolism, 2006. DOI: 10.1152/ajpendo.00201.2006. PMID: [16822960].
• A GHRH gene-targeted model publication relevant to pathway research — Endocrinology, 2004. DOI: 10.1210/en.2004-0119. PMID: [15155578].

REFERENCES

1. National Center for Biotechnology Information. CJC-1295 compound record. PubChem. Accessed 2026.
2. Jetté L, Léger R, Thibaudeau K, Benquet C, Paradis V, van Wyk P, Pham K, Bridon DP. Academic study identifying CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005. DOI: 10.1210/en.2004-1286. PMID: 15817669.
3. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Academic pharmacokinetic study of CJC-1295 as a long-acting GHRH analog. Journal of Clinical Endocrinology & Metabolism. 2006. DOI: 10.1210/jc.2005-1536. PMID: 16352683.
4. National Center for Biotechnology Information. GHRHR gene record. NCBI Gene. Accessed 2026.
5. UniProt Consortium. Human growth hormone-releasing hormone receptor entry Q02643. UniProtKB/Swiss-Prot. Accessed 2026.
6. Lin-Su K, Wajnrajch MP. Review of growth hormone-releasing hormone and the GHRH receptor. Reviews in Endocrine and Metabolic Disorders. 2002. DOI: 10.1023/a:1020949507265. PMID: 12424433.
7. Mayo KE, et al. Review of GHRH synthesis and signaling. Recent Progress in Hormone Research. 1995. PMID: 7740167.
8. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Preclinical GHRH knockout model study of CJC-1295. American Journal of Physiology-Endocrinology and Metabolism. 2006. DOI: 10.1152/ajpendo.00201.2006. PMID: 16822960.
9. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. CJC-1295 and serum protein profile research. Growth Hormone & IGF Research. 2009. DOI: 10.1016/j.ghir.2009.03.001. PMID: 19386527.
10. Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Analytical identification study of CJC-1295. Drug Testing and Analysis. 2010. DOI: 10.1002/dta.233. PMID: 21204297.
11. Mant CT, Hodges RS. HPLC analysis and purification of peptides. Methods in Molecular Biology. 2007. PMID: 18604941.
12. Karpievitch YV, Polpitiya AD, Anderson GA, Smith RD, Dabney AR. LC-MS-based proteomics overview. Annals of Applied Statistics. 2010. DOI: 10.1214/10-AOAS341. PMID: 21593992.
13. International Council for Harmonisation. Q2(R2): Validation of Analytical Procedures. ICH. 2023.
14. U.S. Food and Drug Administration. Analytical procedures and methods validation guidance. FDA Guidance. 2015.
15. International Council for Harmonisation. Q1A(R2): Stability Testing of New Drug Substances and Products. ICH. 2003.
16. Zapadka KL, Becher FJ, Gomes dos Santos AL, Jackson SE. Peptide physical stability review. Interface Focus. 2017. DOI: 10.1098/rsfs.2017.0030. PMID: 29166030.
17. U.S. Food and Drug Administration. RUO and IUO labeling guidance. FDA Guidance. 2013.

---

Research Disclaimer

This material is supplied strictly for in vitro laboratory research and is not for human or veterinary use. Published studies describe specific experimental materials, models, and methods; they do not establish the safety, efficacy, or suitability of this catalog product for non-research use. Review the original publications and the lot-specific analytical documentation independently.